Is Acumen Pharmaceuticals (NASDAQ:ABOS) Using Debt In A Risky Way?
Infor Acquires Acumen and Albanero
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights From Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC) 2024
Accorded Launches Latest Offering, Accorded Acumen: The Actuarial Data Transformation Platform
BTIG Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $11
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)
Buy Rating Justified: Acumen Pharmaceuticals' Promising Position in Alzheimer's Treatment Market
Express News | HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Acumen Pharmaceuticals' Sabirnetug: A Novel Approach in Alzheimer's Disease Treatment Warrants a Buy Rating
Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
Acumen Pharmaceuticals | 10-Q: Quarterly report
Earnings Call Summary | Acumen Pharmaceuticals(ABOS.US) Q1 2024 Earnings Conference
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Acumen Pharmaceuticals Begins Phase 2 Trial and Updates Finances
Express News | Acumen Pharmaceuticals Inc Q1 Shr View $-0.26 -- Lseg Ibes Data
Express News | Acumen Pharmaceuticals Inc - Qtrly Shr Loss $0.25
Express News | Acumen Pharmaceuticals Inc - Cash Is Expected to Support Current Clinical and Operational Activities Into First Half of 2027
Express News | Acumen Pharmaceuticals Q1 2024 GAAP EPS $(0.25) Beats $(0.27) Estimate
Express News | Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights